Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Retrospective Review Of Combined Sirolimus And Simvastatin Therapy In Lymphangioleiomyomatosis.
[lymphangioleiomyomatosis]
Background
.
Combined
simvastatin
and
sirolimus
therapy
reduce
TSC
2
-
null
lesions
and
alveolar
destruction
in
a
mouse
model
of
lymphangioleiomyomatosis
(
LAM
)
,
suggesting
that
therapy
with
both
drugs
may
benefit
LAM
patients
.
Methods
.
To
determine
whether
simvastatin
changed
the
prevalence
of
adverse
events
or
altered
the
therapeutic
effects
of
sirolimus
,
we
recorded
adverse
events
and
changes
in
lung
function
in
LAM
patients
treated
with
simvastatin
plus
sirolimus
(
n
=
14
)
,
sirolimus
(
n
=
44
)
,
or
simvastatin
(
n
=
20
)
.
Results
.
Sirolimus-related
adverse
events
in
the
simvastatin
plus
sirolimus
,
and
sirolimus
only
groups
,
were
64
and
66
%
for
stomatitis
,
50
and
52
%
for
diarrhea
,
50
and
45
%
for
peripheral
edema
,
36
and
61
%
for
acne
,
36
and
30
%
for
hypertension
,
29
and
27
%
for
proteinuria
,
29
and
27
%
for
leukopenia
,
and
21
and
27
%
for
hypercholesterolemia
.
The
frequency
of
simvastatin-related
adverse
events
in
the
simvastatin
,
and
simvastatin
plus
sirolimus
groups
were
60
and
50
%
for
arthralgias
,
and
35
and
36
%
for
myopathy
.
Before
simvastatin
plus
sirolimus
therapy
,
FEV
1
and
DLCO
yearly
rates
of
change
were
respectively
,
-
1
.
4
±
0
.
2
and
-
1
.
8
±
0
.
2
%
predicted
.
After
simvastatin
plus
sirolimus
therapy
,
these
rates
changed
to
+
1
.
2
±
0
.
5
(
p
=
0
.
635
)
and
+
0
.
3
±
0
.
4
%
predicted
,
respectively
(
p
=
0
.
412
)
.
In
44
patients
treated
with
sirolimus
alone
,
FEV
1
and
DLCO
rates
of
change
were
-
1
.
7
±
0
.
1
and
-
2
.
2
±
0
.
1
%
predicted
before
treatment
,
and
+
1
.
7
±
0
.
3
and
+
0
.
7
±
0
.
3
%
predicted
after
therapy
(
p
<
0
.
001
)
.
Conclusions
.
Therapy
with
sirolimus
and
simvastatin
does
not
increase
the
prevalence
of
drug
adverse
events
or
alter
the
therapeutic
effects
of
sirolimus
.
Combined
simvastatin
and
sirolimus
therapy
reduce
TSC
2
-
null
lesions
and
alveolar
destruction
in
a
mouse
model
of
lymphangioleiomyomatosis
(
LAM
)
,
suggesting
that
therapy
with
both
drugs
may
benefit
LAM
patients
.
To
determine
whether
simvastatin
changed
the
prevalence
of
adverse
events
or
altered
the
therapeutic
effects
of
sirolimus
,
we
recorded
adverse
events
and
changes
in
lung
function
in
LAM
patients
treated
with
simvastatin
plus
sirolimus
(
n
=
14
)
,
sirolimus
(
n
=
44
)
,
or
simvastatin
(
n
=
20
)
.
Sirolimus-related
adverse
events
in
the
simvastatin
plus
sirolimus
,
and
sirolimus
only
groups
,
were
64
and
66
%
for
stomatitis
,
50
and
52
%
for
diarrhea
,
50
and
45
%
for
peripheral
edema
,
36
and
61
%
for
acne
,
36
and
30
%
for
hypertension
,
29
and
27
%
for
proteinuria
,
29
and
27
%
for
leukopenia
,
and
21
and
27
%
for
hypercholesterolemia
.
The
frequency
of
simvastatin-related
adverse
events
in
the
simvastatin
,
and
simvastatin
plus
sirolimus
groups
were
60
and
50
%
for
arthralgias
,
and
35
and
36
%
for
myopathy
.
Before
simvastatin
plus
sirolimus
therapy
,
FEV
1
and
DLCO
yearly
rates
of
change
were
respectively
,
-
1
.
4
±
0
.
2
and
-
1
.
8
±
0
.
2
%
predicted
.
After
simvastatin
plus
sirolimus
therapy
,
these
rates
changed
to
+
1
.
2
±
0
.
5
(
p
=
0
.
635
)
and
+
0
.
3
±
0
.
4
%
predicted
,
respectively
(
p
=
0
.
412
)
.
In
44
patients
treated
with
sirolimus
alone
,
FEV
1
and
DLCO
rates
of
change
were
-
1
.
7
±
0
.
1
and
-
2
.
2
±
0
.
1
%
predicted
before
treatment
,
and
+
1
.
7
±
0
.
3
and
+
0
.
7
±
0
.
3
%
predicted
after
therapy
(
p
<
0
.
001
)
.
Therapy
with
sirolimus
and
simvastatin
does
not
increase
the
prevalence
of
drug
adverse
events
or
alter
the
therapeutic
effects
of
sirolimus
.
Diseases
Validation
Diseases presenting
"lung function"
symptom
allergic bronchopulmonary aspergillosis
congenital diaphragmatic hernia
lymphangioleiomyomatosis
monosomy 21
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom